Risk Factors for Treatment Drop-Out: Implications for Adverse Outcomes When Treating Opioid Use Disorder

REFERENCES

• Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995). Buprenorphine treatment of refractory depression. Journal Clinical Psychopharmacology, 15(1), 49–57. https://doi.org/10.1097/00004714-199502000-00008
   PubMed Web of Science ®Google Scholar
• Brorson, H. H., Arnevik, E. A., Rand-Hendriksen, K., & Duckert, F. (2013). Drop-out from addiction treatment: A systematic review of risk factors. Clinical Psychology Review, 33(8), 1010–1024. https://doi.org/10.1016/j.cpr.2013.07.007
   PubMed Web of Science ®Google Scholar
• Copeland Center for Wellness and Recovery. (2018). What is Wrap?. Retrieved September 6, 2019, from https://copelandcenter.com/wellness-recovery-action-plan-wrap
   Google Scholar
• Curran, G. M., Kirchner, J. E., Worley, M., Rookey, C., & Booth, B. M. (2002). Depressive symptomatology and early attrition from intensive outpatient substance use treatment. Journal of Behavioral Health Res, 29(2), 38–43. https://doi.org/10.1007/BF02287700
   Web of Science ®Google Scholar
• Dreifuss, J. A., Griffin, M. L., Frost, K., Fitzmaurice, G. M., Potter, J. S., Fiellin, D. A., & Weiss, R. D. (2013). Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug and Alcohol Dependence, 131, 112–118. https://doi.org/10.1016/j.drugalcdep.2012.12.010
   PubMed Web of Science ®Google Scholar
• Emrich., H. M., Vogt, P., & Herz, A. (1982). Possible antidepressive effects of opioids: Action of buprenorphine. Academy of Science, 398(1), 108–112. https://doi.org/10.1111/j.1749-6632.1982.tb39483.x
   Web of Science ®Google Scholar
• Evren, C., Karabulut, V., Can, Y., Bozkurt, M., & Umut, G. (2014). Predictors of outcome during a 6-month follow-up among heroin dependent patients receiving Buprenorphine/Naloxone maintenance treatment. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 24(4), 311–322. https://doi.org/10.5455/bcp.20140310072258
   Web of Science ®Google Scholar
• Feelemyer, J., Jarlais, D. D., Arasteh, K., Abdul-Quader, A. S., & Hagan, H. (2014). Retention of participants in medication-assisted programs in low- and middle-income countries. An international systematic review. Addiction, 109(1), 20–32. https://doi.org/10.1111/add.12303
   PubMed Web of Science ®Google Scholar
• Flynn, S. M., Epperly, P. M., Davenport, A. T., Cami-Kobeci, G., Husbands, S. M., Ko, M. C., & Czoty, P. W. (2019). Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys. Neuropsychopharmacology, 44(8), 1476–1484. https://doi.org/10.1038/s41386-019-0390-z
   PubMed Web of Science ®Google Scholar
• Gerra, G., Borella, F., Zaimovic, A., Moi, G., Bussandri, M., Bubici, C., & Bertacca, S. (2004). Buprenorphine versus methadone for opioid dependence: Predictor variables for treatment outcome. Drug Alcohol Dependence, 75(1), 37–45. https://doi.org/10.1016/j.drugalcdep.2003.11.017
   PubMed Web of Science ®Google Scholar
• Hawkins, E. J., Baer, J. S., & Kivlahan, D. R. (2007). Concurrent monitoring of psychological distress and satisfaction measures as predictors of addiction treatment retention. Journal of Substance Abuse Treatment, 35(2), 207–216. https://doi.org/10.1016/j.jsat.2007.10.001
   PubMed Web of Science ®Google Scholar
• Health Resources and Services Administration. (2019). Opioid Crisis. Retrieved September 6, 2019, from https://www.hrsa.gov/opioids
   Google Scholar
• Hser, Y. I., Saxon, A. J., & Huang, D. (2014). Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction, 109(1), 79–87. https://doi.org/10.1111/add.12333
   PubMed Web of Science ®Google Scholar
• Hubbard, R. L., Craddock, S. G., & Anderson, J. (2003). Overview of 5-year follow-up outcomes in the drug abuse treatment outcome studies (DATOS). Journal of Substance Abuse Treatment, 5(3), 125–134. https://doi.org/10.1016/S0740-5472(03)00130-2
   Google Scholar
• Lee, J., Nunes, E. B., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, B., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., King, J., Lindblad, R., Liu, D., Matthews, A. G., May, K., Peavy, M., Ross, S., Salazar, D., Schkolnik, P., Shmueli-Blumberg, D., … Rotrosen, J. (2018). Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): A multicentre, open-label, randomised controlled trial. The Lancet, 391(10118), 309–318. https://doi.org/10.1016/S0140-6736(17)32812-X
   PubMed Web of Science ®Google Scholar
• Marcovitz, D. E., McHugh, K., Volpe, J., Votaw, V., & Connery, H. (2016). Predictors of early dropout in buprenorphine/naloxone treatment. The American Journal of Addictions, 25(6), 472–476. https://doi.org/10.1111/ajad.12414
   PubMed Web of Science ®Google Scholar
• McElrath, K. (2018). Medication-assisted treatment for opioid addiction in the United States: Commentary and critique. Substance Use and Misuse, 53(2), 334–343. https://doi.org/10.1080/10826084.2017.1342662
   PubMed Web of Science ®Google Scholar
• Monico, L., Mitchell, S. G., Gryczynski, J., Schwartz, R., O’Grady, K., Yngvild, K. O., & Jaffe, J. (2015). Prior experience with non-prescribed buprenorphine: Role in treatment entry and retention. Journal of Substance Abuse Treatment, 10(57), 57–62. https://doi.org/10.1016/j.jsat.2015.04.010
   Google Scholar
• New York City Department of Health. (2017). Health department releases 2016 drug overdose death data in New York City — 1,374 deaths confirmed, A 46 percent increase from 2015. Retrieved September 6, 2018, from https://www1.nyc.gov/site/doh/about/press/pr2017/pr048-17
   Google Scholar
• New York State Department of Health.(2020, July). Delivery System Reform Incentive Payment (DSRIPP) Program. Retrieved November 6, 2020 fromhttps://www.health.ny.gov/health_care/medicaid/redesign/dsrip/
   Google Scholar
• NIDA. (2016, November 1). Effective Treatments for Opioid Addiction. Retrieved November 6, 2020, fromhttps://www.drugabuse.gov/publications/effective-treatments-opioid-addiction
   Google Scholar
• NIDA. (2020, June 3). How effective is drug addiction treatment?. Retrieved November 6, 2020, fromhttps://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/frequently-asked-questions/how-effective-drug-addiction-treatment
   Google Scholar
• Nunes, E. V., Bosaga., A., Krupitsky, E., Nangia, N., Silverman, B., Akerman, S., & Sullivan, M. (2019). Opioid use and dropout from extended-release naltrexone in a controlled trial: Implications for mechanism. Addiction, 115(2), 239–246. doi:10.1111/add.14735
   Google Scholar
• Schuman-Olivier, Z., Weiss, R. D., Hoeppner., B. B., Borodovsky., J., & Albanese., M. J. (2014). Emerging adult age status predicts poor buprenorphine treatment retention. Journal of Substance Abuse Treatment, 47(3), 202–212. https://doi.org/10.1016/j.jsat.2014.04.006
   PubMed Web of Science ®Google Scholar
• Soeffing, J. M., Martin, L. D., Fingerhood, M. I., Jasinski, D. R., & Rastegar, D. A. (2009). Buprenorphine maintenance treatment in a primary care setting: Outcomes at 1 year. Journal of Substance Abuse Treatment, 37(4), 426–430.  https://doi.org/10.1016/j.jsat.2009.05.003
   Google Scholar
• Solmaz, A., Hirchak, K., Lutz, R., McDonell, M. G., McPherson, S. M., Roll, J. M., & Amram, O. (2018). Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. Drug and Alcohol Dependence, 193(1), 63–68. http://10.1016/j.drugalcdep.2018.08.024.
   Web of Science ®Google Scholar
• Soyka, M., Zingg, C., Koller, G., & Kuefner, H. (2008). Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. International Journal of Neuropsychopharmacology, 11(5), 641–653. https://doi.org/10.1017/S146114570700836X
   PubMed Web of Science ®Google Scholar
• Stein, M. D., Cioe, P., & Friedmann, P. D. 2005. Buprenorphine retention in primary care. Journal of General Internal Medicine, 11(20), 1038–1041. https://doi.org/10.1111/j.1525-1497.2005.0228.x
   Google Scholar
• Substance Abuse and Mental Health Services. (2020, August 13). Youth and Young Adults. Retrieved November 6, 2020, from https://www.samhsa.gov/brss-tacs/recovery-support-tools/youth-young-adults
   Google Scholar
• Tate, S. R., Mrnak-Meyer, J., Shriver, C. L., Atkinson, J. H., Robinson, S. K., & Brown, S. A. (2011). Predictors of treatment retention for substance-dependent adults with co-occurring depression. The American Journal on Addictions, 20(4), 357–365. https://doi.org/10.1111/j.1521-0391.2011.00137.x
   PubMed Web of Science ®Google Scholar
• Tibshirani, R. J., & Efron, B. (1993). Introduction to the Bootstrap, New York. Chapman & Hall.
   Google Scholar
• United States Department of Health and Human Services.(2019). What is the U.S. Opioid Epidemic?. Retrieved from https://www.hhs.gov/opioids/about-the-epidemic/index.html
   Google Scholar